Food Safety Incidents

Suggestion of therapeutic properties has been detected in Dietary supplement glamorous ozem.

Written by SGS Digicomply Editorial Team | Feb 27, 2026 11:00:00 PM

Food Safety Incident Report

Date: February 12, 2026

A recent incident has emerged concerning a dietary supplement that has been suggested to possess therapeutic properties. This incident was reported by the Brazilian Health Regulatory Agency, known as ANVISA, and originates from Brazil.

The dietary supplement in question has raised concerns due to the implications of its suggested health benefits. While dietary supplements can play a role in nutrition and wellness, it is crucial to ensure that any claims regarding therapeutic properties are substantiated by scientific evidence and comply with regulatory standards.

Consumers are advised to exercise caution when considering dietary supplements that claim to offer health benefits. It is essential to consult with healthcare professionals before incorporating such products into one's diet, especially if they are intended for therapeutic use.

Regulatory agencies like ANVISA play a vital role in monitoring and controlling the safety and efficacy of dietary supplements. This incident highlights the importance of ongoing vigilance in the marketplace to protect consumers from potentially misleading claims and ensure that products meet safety standards.

As this situation develops, further updates will be provided to inform the public about the safety and regulatory status of the dietary supplement in question.

  • Incident: Suggestion of therapeutic properties has been detected in Dietary supplement glamorous ozem.
  • Date: 2026-02-12
  • Product: Dietary supplement glamorous ozem
  • Market: Available to SGS Digicomply users only. Explore the platform (for enterprises, no individual plans)
  • Origin of issue: Brazil
  • Hazard: Available to SGS Digicomply users only. Explore the platform (for enterprises, no individual plans)
  • Incident Category: Control
  • Source: Brazilian Health Regulatory Agency - ANVISA